Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 15Rectal Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Multiple Myeloma 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Carboplatin 784Pemetrexed 607Cisplatin 545Paclitaxel 491pembrolizumab 464Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 258Nivolumab 244Bevacizumab 233osimertinib 178Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 133Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 84Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × trastuzumab biosimilar HLX02 × Clear all
NCT04285671 2026-03-10

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Active not recruiting
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡